Company news
Pliant Therapeutics, Inc. news in 2022
Pliant Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis
December 14, 2022
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 7, 2022
Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary/Lung Disease Mini-Symposium
October 4, 2022
Pliant Therapeutics Announces Appointment of Katharine Knobil, M.D. to Board of Directors
September 14, 2022
Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis
August 31, 2022
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 7, 2022
Pliant Therapeutics to Participate in BTIG Biotechnology Conference
August 1, 2022
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Primary Sclerosing Cholangitis
July 20, 2022
Pliant Therapeutics Announces Pricing of Upsized $200.0 Million Public Offering
July 11, 2022
Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis
July 9, 2022
Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022 Highlighting Preclinical and Clinical Data in Support of the INTEGRIS-PSC Phase 2a Clinical Trial
June 23, 2022
Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies
June 21, 2022
Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration
June 15, 2022
Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022
June 14, 2022
Pliant Therapeutics Announces Presentations at 2022 American Thoracic Society International Conference
May 17, 2022
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 8, 2022
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis
May 2, 2022
Pliant Therapeutics Announces Multiple Presentations at the 2022 American Thoracic Society International Conference
May 1, 2022
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
February 27, 2022
Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF-β Signaling in Healthy Volunteers
February 27, 2022
Pliant Therapeutics Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis
February 23, 2022
Decks in 2022
- 2022 New Directions in Biology and Disease of Skeletal Muscle Conference
Conference · 25 slides · November 2022
- Investor Presentation (January 2022)
Investor deck · 29 slides · Jan 10, 2022